RP463: a stabilized technetium-99m complex of a hydrazino nicotinamide derivatized chemotactic peptide for infection imaging.
A HYNIC-conjugated chemotactic peptide (fMLFK-HYNIC) was labeled with (99m)Tc using tricine and TPPTS as coligands. The combination of fMLFK-HYNIC, tricine, and TPPTS with (99m)Tc produced a ternary ligand complex [(99m)Tc(fMLFK-HYNIC)(tricine)(TPPTS)] (RP463). RP463 was synthesized either in two steps, in which the binary ligand complex [(99m)Tc(fMLFK-HYNIC)(tricine)(2)] (RP469) was formed first and then reacted with TPPTS, or in one step by direct reduction of [(99m)Tc]pertechnetate with stannous chloride in the presence of fMLFK-HYNIC, tricine, and TPPTS. The radiolabeling yield for RP463 was usually >/=90% using 10 microg of fMLFK-HYNIC and 100 mCi of [(99m)Tc]pertechnetate. Unlike RP469, which decomposed rapidly in the absence of excess tricine coligand, RP463 was stable in solution for at least 6 h. [(99)Tc]RP463 was prepared and characterized by HPLC and electrospray mass spectrometry. In an in vitro assay, [(99)Tc]RP463 showed an IC(50) of 2 nM against binding of [(3)H]fMLF to receptors on PMNs. [(99)Tc]RP463 also induces effectively the superoxide release of polymorphonuclear leukocytes (PMNs) with an EC(50) value of 0.2 +/- 0.2 nM. The localization of RP463 in the infection foci was assessed in a rabbit infection model. RP463 was cleared from the blood faster than RP469 and was excreted mainly through the renal system. As a result of rapid blood clearance and increased uptake, the target-to-background ratios continuously increased from 1.5 +/- 0.2 at 15 min postinjection to 7.5 +/- 0.4 at 4 h postinjection. Visualization of the infected area could be as early as 2 h. A transient decrease in white blood cell count of 35% was observed during the first 30 min after injection of the HPLC-purified RP463 in the infected rabbit. This suggests that future research in this area should focus on developing highly potent antagonists for chemotactic peptide receptor or other receptors on PMNs and monocytes.
Edwards
D S
DS
McNeil Consumers Products, 7050 Camp Hill Road, Fort Washington, Pennsylvania 19034, USA.
Liu
S
S
Ziegler
M C
MC
Harris
A R
AR
Crocker
A C
AC
Heminway
S J
SJ
Barrett
J A
JA
Bridger
G J
GJ
Abrams
M J
MJ
Higgins
J D
JD
D000038:Abscess / Q000097:blood / Q000175:diagnosis*; D000818:Animals; D002630:Chemotactic Factors / Q000097:blood / Q000138:chemical synthesis* / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D004927:Escherichia coli Infections / Q000097:blood / Q000175:diagnosis*; D005260:Female; D006801:Humans; D007536:Isomerism; D009135:Muscular Diseases / Q000097:blood / Q000175:diagnosis*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism; D009842:Oligopeptides / Q000097:blood / Q000138:chemical synthesis* / Q000737:chemistry; D015609:Organotechnetium Compounds / Q000097:blood / Q000138:chemical synthesis* / Q000737:chemistry; D011817:Rabbits; D019275:Radiopharmaceuticals / Q000097:blood / Q000138:chemical synthesis*; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic / Q000378:metabolism; D018000:Receptors, Peptide / Q000378:metabolism; D012996:Solutions; D014316:Tritium
C400059:99mTc(fMLFK-HYNIC)(tricine)(TPPTS); C400060:99mTc(fMLFK-HYNIC)(tricine)2; D002630:Chemotactic Factors; D009842:Oligopeptides; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic; D018000:Receptors, Peptide; D012996:Solutions; D014316:Tritium; D009240:N-Formylmethionine Leucyl-Phenylalanine; C049813:N-formylmethionyl-leucyl-phenylalanyl-lysine